Next Article in Journal
Structural Insights in Multifunctional Papillomavirus Oncoproteins
Previous Article in Journal
Human Cytomegalovirus Nuclear Capsids Associate with the Core Nuclear Egress Complex and the Viral Protein Kinase pUL97
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Viruses 2018, 10(1), 38; https://doi.org/10.3390/v10010038

A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response

1
College of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing 100044, China
2
Department of Pediatrics, Emory University and Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA
3
Beijing Institute of Biotechnology, Beijing 100071, China
These authors contributed equally to this work.
*
Authors to whom correspondence should be addressed.
Received: 30 November 2017 / Revised: 8 January 2018 / Accepted: 9 January 2018 / Published: 15 January 2018
(This article belongs to the Section Antivirals & Vaccines)
View Full-Text   |   Download PDF [3927 KB, uploaded 15 January 2018]   |  

Abstract

Human respiratory syncytial virus (RSV) is the most significant cause of acute lower respiratory infection in children. However, there is no licensed vaccine available. Here, we investigated the effect of five or 20 copies of C-Class of CpG ODN (CpG-C) motif incorporated into a plasmid DNA vaccine encoding RSV fusion (F) glycoprotein on the vaccine-induced immune response. The addition of CpG-C motif enhanced serum binding and virus-neutralizing antibody responses in BALB/c mice immunized with the DNA vaccines. Moreover, mice vaccinated with CpG-modified vaccines, especially with the higher 20 copies, resulted in an enhanced shift toward a Th1-biased antibody and T-cell response, a decrease in pulmonary pathology and virus replication, and a decrease in weight loss after RSV challenge. This study suggests that CpG-C motif, cloned into the backbone of DNA vaccine encoding RSV F glycoprotein, functions as a built-in adjuvant capable of improving the efficacy of DNA vaccine against RSV infection. View Full-Text
Keywords: human respiratory syncytial virus; CpG oligodeoxynucleotide; DNA vaccine; built-in adjuvant; protective immunity human respiratory syncytial virus; CpG oligodeoxynucleotide; DNA vaccine; built-in adjuvant; protective immunity
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Ma, Y.; Jiao, Y.-Y.; Yu, Y.-Z.; Jiang, N.; Hua, Y.; Zhang, X.-J.; Fu, Y.-H.; Peng, X.-L.; Zheng, Y.-P.; Anderson, L.J.; He, J.-S. A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response. Viruses 2018, 10, 38.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top